111 / 140
233
subjects. Br J Clin Pharmacol. 2007 Sep; 64(3):292-303.
18. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A,
et al. RE-LY Steering Committee and Investigators. Dabigatran versus
warfarin in patients with atrial fibrillation.N Engl J Med. 2009 Sep
17; 361(12):1139-51.
19. Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly
PA,The Long-Term Multicenter Observational Study of Dabigatran
Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Circulation. 2013 Jul 16; 128(3):237-43.
20. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model
of the pharmacokinetics and pharmacodynamics of rivaroxaban--an
oral, direct factor Xa inhibitor--in healthy subjects. Int J Clin
Pharmacol Ther. 2007 Jun; 45(6):335-44.
21. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral,
direct factor Xa inhibition compared with vitamin K antagonism
for prevention of stroke and Embolism Trial in Atrial Fibrillation:
rationale and design of the ROCKET AF study. Am Heart J. 2010 Mar;
159(3):340-347.
22. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al.
ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular
atrial fibrillation. N Engl J Med. 2011 Sep 8; 365(10):883-91.
23. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al.
Apixaban metabolism and pharmacokinetics after oral administration
to humans. Drug Metab Dispos. 2009 Jan; 37(1):74-81.
24. Shantsila E, Lip GY. Apixaban, an oral, direct inhibitor of activated
Factor Xa. Curr Opin Investig Drugs. 2008 Sep; 9(9):1020-33.
25. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety,
pharmacokinetics and pharmacodynamics of multiple oral doses of
apixaban,a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol.
2013 Nov; 76(5):776-86.
26. Connolly S, Eikelboom M, Campbell J, Diener HC, Hart R, et al.
Apixaban in Atrial Fibrillation. AVERROES Trial.NEJM 2011, 364.806-
17.
27. Lopes RD, Alexander JH, Al- Khatib SM, Ansell J, Diaz R, Easton JD, et
al. ARISTOTLE Investigators. Apixaban for reduction in stroke and other
Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design
and rationale. Am Heart J. 2010 Mar; 159(3):331-9.
28. Granger C, Alexander J, Mc Murray J, Lopes R, Hylek E, Hanna M, et al.
Apixaban versus warfarin in patients with atrial fibrillation. ARISTOTLE
Trial NEJM 2011; 365: 981-992.
29. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T,
Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and
pharmacodynamics of the novel factor Xa inhibitor edoxaban in
healthy volunteers. J Clin Pharmacol. 2010 Jul; 50 (7):743-53.
30. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri
M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared
with warfarin in patients with atrial fibrillation: design and rationale
for the Effective antticoagulation with factor Xa next Generation in
Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48
(ENGAGE AF-TIMI 48). Am Heart J. 2010 Oct; 160(4):635-41.
31. Giugliano R, Ruff C, Braunwald E, Murphy s, Wivioot S,Halperin J, et
al. Edoxaban versus warfarin in patients with atrial fibrillation. NEJM
2013, 369: 2093-104.
32. Camm J, Lip G, De Caterine R, Savelieva I, Atar D, et al. Focussed
update on the ESC Guidelines for the management of atrial fibrillation
European Heart Journal 2012 ; 33: 2719-2747.
33. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS,et
al. Canadian Cardiovascular Society Atrial Fibrillation Guidelines
Committee. Focused 2012 update of the Canadian Cardiovascular
Society atrial fibrillation guidelines: recommendations for stroke
prevention and rate/rhythm control. Can J Cardiol. 2012 Mar-Apr;
28(2):125-36.
34. Kernan W, et al. Stroke .Guidelines for the prevention of Stroke in
patients with stroke and transient ischemic attack: A guideline
for healthcare professionals from the American Heart Asociation/
American Stroke Association. 2014,may 1, online.
35. January C,Wann S,Alpert J, Calkin H, ClevelanD J, et al.2014 AHA/ACC,/
HRS Guideline for the management of patients with atrial fibrillation.
Circulation, 2014; march 28.
[NUEVOS ANTICOAGULANTES ORALES EN FIBRILACIÓN AURICULAR - Dra. E. Marianella Seguel R.]